Unknown PHASE1 INTERVENTIONAL 5-arm NCT06164327

Study of BEBT-908 Combined With Drugs in the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

A Multicenter, Open Phase Ib Study of the Safety and Efficacy of BEBT-908 Combined With Drugs in the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Sponsor: BeBetter Med Inc

Conditions Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Interventions BEBT-908 for Injection Carboplatin Injection Etoposide Injection Gemcitabine Hydrochloride for Injection Ifosfamide for Injection Oxaliplatin Injection Rituximab Injection

Updated 4 times since 2024 Last updated: Dec 1, 2023 Started: Dec 1, 2023 Primary completion: Oct 31, 2025 Completion: Nov 5, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06164327, this PHASE1 trial focuses on Relapsed/Refractory Diffuse Large B-Cell Lymphoma and remains ongoing. Sponsored by BeBetter Med Inc, it has been updated 4 times since 2023, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

4 versions recorded

Feb 2026 — Present [monthly]

Unknown PHASE1

Status: Recruiting → Unknown
Sep 2024 — Feb 2026 [monthly]

Recruiting PHASE1
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE1
Jan 2024 — Jul 2024 [monthly]

Recruiting PHASE1

First recorded

Dec 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

BeBetter Med Inc

Data source: BeBetter Med Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China